Brought to you by 
F-star Alpha spins out of F-star GMBH; raises €9.4mm through Series A round
22 Jun 2022
Executive Summary
Austrian cancer company F-star GMBH has spun out some of its oncology assets into F-star Alpha Ltd. The new independent company concurrently raised €9.4mm ($12.9mm) through a Series A round from Atlas Venture, Asecap Venture, TVM Capital, SR One, MP Healthcare Venture Management, and MS Ventures (formerly Merck Serono Ventures). F-star Alpha’s first preclinical project in-licensed from its originator is FS102 for breast, gastric, and colorectal cancers.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
F-star Alpha spins out of F-star GMBH; raises €9.4mm through Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice